Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy

被引:10
|
作者
Kaulsay, Ranbir [1 ]
Duc Tung Nguyen [2 ]
Kuhl, Hans Christian [2 ]
机构
[1] Beacon Hosp, Beacon ENT & Allergy Clin, Bon Secours Consultant Private Clin, Dublin, Ireland
[2] Meda Pharma GmbH & Co KG, Bad Homburg, Germany
关键词
azelastine hydrochloride; endoscopy; fluticasone propionate; Ireland; MP-AzeFlu; persistent allergic rhinitis; QUALITY-OF-LIFE; INTRANASAL THERAPY; SLEEP IMPAIRMENT; PRIMARY-CARE; LONG-TERM; IMPACT; MP29-02; CONGESTION; INFLAMMATION; FLUTICASONE;
D O I
10.1002/iid3.237
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Most allergic rhinitis (AR) patients have moderate-to-severe, persistent disease. Meda Pharma's AzeFlu (MP-AzeFlu) combines intranasal azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel formulation in a single device to treat AR. This prospective, noninterventional study sought to assess the effectiveness of MP-AzeFlu (one spray/nostril twice daily; 548 mu g AZE/200 mu g FP daily dose) in relieving AR symptom severity. Methods Results A visual analogue scale (VAS) was used prior to MP-AzeFlu treatment on days 0, 1, 3, 7, 14, 21, 28, 35, and 42 by 53 persistent AR (PER) patients seen in routine clinical practice in Ireland. An endoscopy was performed on days 0 and 28, and symptoms of edema, discharge, and redness were scored on a three-point scale (for both nostrils). Patients using MP-AzeFlu experienced rapid VAS score reduction from 73.4 mm (standard deviation [SD], 20.3) at Day 0 to 31.5 mm (SD, 25.0) at day 28 (P < 0.0001) to 28.1 mm (SD, 24.1) at day 42 (P < 0.0001), a 45.3-mm reduction. On average, patients achieved a clinically relevant VAS score cutoff of 50 mm before Day 7. Total endoscopy score decreased from 7.5 mm (SD, 3.1) at baseline to 3.5 mm (SD, 2.5) at Day 28. The incidence of severe edema on endoscopy decreased from 53.1% at baseline to 3.8% at Day 28. A similar reduction in the incidence of thick/mucousy discharge (from 28.3% to 4.8%) and severe redness (from 34.9% to 0%) was also observed. Conclusions MP-AzeFlu provided effective, rapid control of PER as assessed by VAS in a real-world clinical setting in Ireland. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved mucosal appearance after 28 days. These results confirm the safety of MP-AzeFlu and exceed the efficacy demonstrated in phase 3 clinical studies for controlling AR in PER patients.
引用
收藏
页码:456 / 464
页数:9
相关论文
共 50 条
  • [41] Diagnostic value of specific symptoms for differentiating allergic rhinitis: assessed using a visual analogue scale
    Zhao, Y.
    Zhang, Y.
    He, F.
    Zhang, L.
    B-ENT, 2018, 14 (02) : 85 - 91
  • [42] Effectiveness of desloratadine in improving quality of life in patients with persistent allergic rhinitis
    Kaulsay, R.
    Rampa, S.
    Puraviappan, P.
    ALLERGY, 2007, 62 : 490 - 491
  • [43] Efficacy of MP-AzeFlu versus fluticasone propionate and azelastine in patients with allergic rhinitis and nasal hyperreactivity: A post hoc analysis from three clinical trials
    Hellings, P.
    Kuhl, H.
    Koltun, A.
    Kopietz, F.
    Munzel, U.
    Bernstein, J. A.
    ALLERGY, 2018, 73 : 446 - 447
  • [44] Visual analogue scale in patients with allergic rhinitis: an observational prospective multicenter study
    Demoly, P.
    Devillier, P.
    Bousquet, P.
    Mesbah, K.
    Bousquet, J.
    ALLERGY, 2012, 67 : 339 - 339
  • [45] Allergic rhinitis severity may be assessed using either visual analogue scale or ARIA modified criterion
    Del Cuvillo, A.
    Santos, V
    Montoro, J.
    Bartra, J.
    Davila, I
    Ferrer, M.
    Jauregui, I
    Sastre, J.
    Mullol, J.
    Valero, A.
    ALLERGY, 2012, 67 : 341 - 341
  • [46] MP-AzeFlu for management of allergic rhinitis symptoms in patients ≥65 years: A post hoc efficacy and safety analysis from three pooled phase 3 trials
    Bousquet, J.
    Meltzer, E. O.
    Kuhl, H.
    Koltun, A.
    Kopietz, F.
    Munzel, U.
    ALLERGY, 2018, 73 : 573 - 574
  • [47] Perception of Bronchodilation Assessed by Visual Analog Scale in Asthmatics: A Real-life Study
    Ricciardolo, F. L. M.
    Rindone, E.
    Schiavetti, I
    Ciprandi, G.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2016, 26 (01) : 49 - 51
  • [48] Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: Asthma and Rhinitis
    Demoly, P.
    Bousquet, P. J.
    Mesbah, K.
    Bousquet, J.
    Devillier, P.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2013, 43 (08): : 881 - 888
  • [49] Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany
    Korn, S.
    Thielen, A.
    Seyfried, S.
    Taube, C.
    Kornmann, O.
    Buhl, R.
    RESPIRATORY MEDICINE, 2009, 103 (11) : 1725 - 1731
  • [50] Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis
    Roger, Albert
    Malet, Alfons
    Moreno, Victoria
    Parra, Antonio
    Gutierrez, Diego
    Lleonart, Ramon
    Moreno, Francisco
    Valero, Antonio
    Navarro, Begona
    Hinojosa, Belen
    Justicia, Jose L.
    IMMUNOTHERAPY, 2020, 12 (01) : 53 - 62